— Dupixent sales, which soared by 141% to $633 million, drove higher profitability from antibody collaboration with Sanofi.
— Looking ahead into the full year 2019, the company lowered the Sanofi collaboration revenue outlook to the range of $490 million to $510 million from the prior range of $500 million to $530 million.
ADVERTISEMENT
— Unreimbursed R&D expense, on a reported basis, is now expected to be $2.36 billion to $2.41 billion, and SG&A expense is now predicted to be between $1.73 billion and $1.78 billion for 2019.
— The forecast for capital expenditure is tightened to the range of $390 million to $420 million from the previous range of $380 million to $420 million for the full year.